Key facts
- It has raised $48.4M; the latest was Later Stage VC ($14.1M) in Dec 2024.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Korea Investment Partners, Korea Development Bank, SJ Investment Partners — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Pin Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Pin Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pin Therapeutics
Developer of therapeutic drugs designed to be used for chemical biology-driven protein degradation. The company's drugs utilize the body's natural processes to regulate protein levels using the ubiquitin-proteasome system, enabling doctors to address various diseases, including cancer.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2016
- Employees
- 14
- Website
- pintherapeutics.com/
- Ownership
- Privately Held (backing)
Pin Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pin Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pin Therapeutics in its N-PORT filings yet. We sweep new filings monthly.